Notícias

Coronavirus disease 2019 (Covid-19), caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has come to the fore in Wuhan,...

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative...

By July 14, 2021, 81·3 % of adults (aged ≥18 years) in Chile had received a first SARS-CoV-2 vaccine and...

COVID-19 is caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus (CoV)-2 (SARS-CoV-2). The virus is responsible for...

As expected, several new variants of Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) emerged and have been detected around the world throughout...

We and others have previously demonstrated that the endothelium is a primary target of the severe acute respiratory syndrome coronavirus...

While recent literature has shown the efficacy of the SARS-CoV-2 vaccine in preventing infection, it’s impact on need for emergency...

A FACTO n° 66 aborda o tema inovação. Em sua Matéria Política, destaca as
dificuldades estruturais do Brasil na...

There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the...

The lack of effective treatment options to reduce COVID-19 associated mortality, disease progression, and the need for invasive mechanical ventilation...

ABIFINA em encontro da indústria brasileira com a vice-diretora-geral da Organização
Mundial do Comércio (OMC)

Corona Virus Disease 2019 (COVID-19), referred to as ‘New Coronary Pneumonia’, is a type of acute infectious disease caused by...